Patients With Decompensated Cirrhosis Often Lack Advance Care Plans Patients With Decompensated Cirrhosis Often Lack Advance Care Plans
Many patients with decompensated cirrhosis do not have advance care plans in place to cover their trajectory of illness through end-of-life care, according to a new study that concludes this may be one reason they receive overly aggressive treatment.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - March 17, 2021 Category: Transplant Surgery Tags: Gastroenterology News Source Type: news
Fatty liver disease symptoms: Six signs your condition has become irreversible
FATTY liver disease is pernicious because warning signs may only emerge in the later stages. If fatty liver disease progresses to cirrhosis , it cannot be reversed. Here are six warning signs of cirrhosis. (Source: Daily Express - Health)
Source: Daily Express - Health - March 16, 2021 Category: Consumer Health News Source Type: news
Targeted Albumin Not Better for Hospitalized Cirrhosis Patients
MONDAY, March 8, 2021 -- For patients hospitalized with decompensated cirrhosis, albumin infusions to raise the serum albumin level to a target of 30 g per liter or higher do not improve outcomes compared with standard care, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 8, 2021 Category: Pharmaceuticals Source Type: news
New AASLD Guidelines Reconsider Bleeding Risk in Cirrhosis New AASLD Guidelines Reconsider Bleeding Risk in Cirrhosis
Dr David Johnson comments on the paradigm-shifting implications of these guidelines on coagulation and bleeding in patients with cirrhosis.Medscape Gastroenterology (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - March 4, 2021 Category: Intensive Care Tags: Gastroenterology Commentary Source Type: news
Oncotarget: Effect of liver fibrosis on survival in patients with intrahepatic cholangiocarcinoma
(Impact Journals LLC) The @Oncotarget authors aimed to assess the effect of cirrhosis on outcomes in iCCA patients (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 1, 2021 Category: Cancer & Oncology Source Type: news
Thiazolidinediones and Risk of MACE in T2DM and Cirrhosis Thiazolidinediones and Risk of MACE in T2DM and Cirrhosis
This study investigated the long-term cardiovascular outcomes of thiazolidinedione use in patients with type 2 diabetes and cirrhosis.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 25, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Operational guidelines launched for integration of Non-Alcoholic Fatty Liver Disease with NPCDCS
"Over the last two decades global burden of NASH has more than doubled. Globally, NASH caused 40 lakh prevalent cases of compensated cirrhosis in 1990, which increased to 94 lakh cases in 2017. NAFLD is emerging as an important cause of liver disease in India," Vardhan was quoted as saying in a Health Ministry statement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 22, 2021 Category: Pharmaceuticals Source Type: news
AGA Practice Update: Bariatric Surgery in Patients With Cirrhosis AGA Practice Update: Bariatric Surgery in Patients With Cirrhosis
According to one study cited in the update, approximately 30% of patients with cirrhosis have comorbid obesity, and this figure may increase even further as the epidemic of NAFLD progresses.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - February 8, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
As alcohol abuse rises amid pandemic, hospitals see a wave of deadly liver disease
UCLA, USC and hospitals nationwide are treating more patients for alcoholic hepatitis, cirrhosis and other conditions amid COVID-19 shutdowns. (Source: L.A. Times - Health)
Source: L.A. Times - Health - February 8, 2021 Category: Consumer Health News Authors: Eli Cahan Source Type: news
Rifaximin May Prevent Hepatic Encephalopathy After TIPS Placement for Cirrhosis Rifaximin May Prevent Hepatic Encephalopathy After TIPS Placement for Cirrhosis
The antibiotic rifaximin given before and after transjugular intrahepatic portosystemic shunt (TIPS) placement helped prevent hepatic encephalopathy (HE) in a placebo-controlled trial.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 6, 2021 Category: Surgery Tags: Gastroenterology News Source Type: news
New combination therapy offers chance of healing hepatitis B
(German Center for Infection Research) Around 260 million people, more than three percent of the global population, are chronically infected with the hepatitis B virus (HBV); in the long term, this often leads to complications such as liver cirrhosis and liver cancer. A cure is not yet possible with the available medication. Scientists at the German Center for Infection Research (DZIF) and the University Hospital Eppendorf (UKE) have now investigated a new combination therapy that has proven highly effective in their infection model. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 4, 2021 Category: Infectious Diseases Source Type: news
Rifaximin Prevents Overt Hepatic Encephalopathy After TIPS
MONDAY, Feb. 1, 2021 -- For patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt (TIPS) placement, rifaximin used before and after the procedure is associated with a reduced risk for overt hepatic encephalopathy (HE),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 1, 2021 Category: Pharmaceuticals Source Type: news
Fatty liver disease symptoms: Melena is a sign of the condition
FATTY liver disease could progress to cirrhosis - scarring of the liver - if fat cells continue to build up in the life-supporting organ. How do you know if you're affected by the condition? What are the symptoms? (Source: Daily Express - Health)
Source: Daily Express - Health - January 30, 2021 Category: Consumer Health News Source Type: news
Widespread Liver Disease Missed in Patients With Type 2 Diabetes Widespread Liver Disease Missed in Patients With Type 2 Diabetes
Strikingly high prevalence rates of fatty liver disease, advanced fibrosis, and cirrhosis among patients with type 2 diabetes has led to calls for heightened awareness and screening.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - January 25, 2021 Category: Gastroenterology Tags: Diabetes & Endocrinology News Source Type: news
CT identifies patients with high-risk nonalcoholic fatty liver disease (NAFLD)
(American Roentgen Ray Society) According to ARRS' American Journal of Roentgenology, Fibrosis-4 and multiple CT findings can identify patients with high-risk nonalcoholic fatty liver disease--advanced fibrosis or cirrhosis, that is--though the presence of nonalcoholic steatohepatitis remains elusive on CT. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 22, 2021 Category: Cancer & Oncology Source Type: news
